Three insights:
1. The moldable bone graft substitute consists of bovine collagen and biphasic, hydroxyapatite/ß-tricalcium phosphate granules designed to produce a porous scaffold and sustained osteoconductivity throughout the bone remodeling process.
2. Osteomatrix+ is indicated to be combined with autologous bone marrow aspirate and packed into osseous defects of the extremities, pelvis and posterolateral spine. It is indicated for use as an autograft extender in the posterolateral spine. The device is designed to resorb and be replaced by host bone during the healing process.
3. “Osteomatrix+ represents the first of several next generation products that will be added to the Bioventus portfolio in the next five years,” said Bioventus CEO Tony Bihl.
More articles on biologics:
Biointegrative orthopedic fixation material receives FDA clearance: 5 things to know
Louisiana spine surgeon adopts stem cell therapy options: 5 insights
Generex Biotechnology acquires surgical supplier, distributor for $1M: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
